Qiagen N.V.

Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
  • TickerQIA
  • ISINNL0012169213
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands
Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Offre insuffisante, retour aux fondamentaux - ACHAT (vs APPORTER), OC 52€ (vs 43€)

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Apporter à l'offre relevée - APPORTER vs NEUTRE, OC 43€ (vs 39€)

Expert Corporate Governance Service (ECGS)

Qiagen – AGM 30 June 2020

ECGS notes that as a result of the Covid-19 pandemic the AGM will be held as an electronic meeting only. Consequently, it will not be possible to attend the AGM in person.Under ITEM 5 an advisory vote on the Company' executive remuneration report is requested. ECGS has concerns over excessive payments at QIAGEN. Accordingly, ECGS recommends to vote OPPOSE.Under ITEM 9b it is proposed to re-appoint Mr. Håkan Björklund as Member of the supervisory board. Although Mr. Björklund is considered independent, ECGS has concerns over his aggregate time commitments. Mr. Björklund is serving as Chairman o...

An unfavourable environment weighs on QIAGEN NV, which sees a downgrade to Neutral

The independent financial analyst theScreener just requalified the general evaluation of QIAGEN NV (DE), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as defensive. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Neutral. As of the analysis date May 1, 2020, the closing price was EUR 38.19 and its target price was estimated at EUR 28.67.

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Etude sectorielle Medtech : Détecter les faux positifs

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in eme...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks within the Communications, Health Care, Manufacturing, Materials, Technology, Transportation, and U...

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Offre insuffisante, retour aux fondamentaux - ACHAT (vs APPORTER), OC 52€ (vs 43€)

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Apporter à l'offre relevée - APPORTER vs NEUTRE, OC 43€ (vs 39€)

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Etude sectorielle Medtech : Détecter les faux positifs

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior